FOLFOX/bevacizumab plus /- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

被引：0
|
作者：
Schmoll, H. [1 ]
Garlipp, B. [2 ]
Junghanss, C. [3 ]
Vogel, A. [4 ]
Kaiser, U. [5 ]
Florschuetz, A. [6 ]
Kanzler, S. [7 ]
Hannig, C.
Meinert, F. [1 ]
Cygon, F. [1 ]
Stein, A. [8 ]
机构：
[1] Martin Luther Univ Halle Wittenberg, Halle, Germany
[2] Uniklin Magdeburg, Magdeburg, Germany
[3] Univ Rostock, Rostock, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Bernward Krankenhaus, Hildesheim, Germany
[6] Stadtisches Klinikum Dessau, Dessau, Germany
[7] Leopoldina Krankenhaus Schweinfurt, Med Klin 2, Schweinfurt, Germany
[8] Univ Med Ctr Hamburg, Hamburg, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 023
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CHARTA: FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer - long term outcome
    Meinert, F.
    Schmoll, H. -J
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C., V
    Hildebrandt, B.
    Steighardt, J.
    Cygon, F.
    Stein, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 245 - 245
  • [2] "CHARTA": FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer; a multivariate analysis of prognostic and predictive factors
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Schmoll, H. -J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 162 - 162
  • [3] FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis
    Hans-Joachim, Schmoll
    Benjamin, Garlipp
    Christian, Junghanss
    Malte, Leithaeuser
    Arndt, Vogel
    Michael, Schaefers
    Ulrich, Kaiser
    Heinz-Gert, Hoeffkes
    Axel, Florschuetz
    Joern, Ruessel
    Stephan, Kanzler
    Thomas, Edelmann
    Helmut, Forstbauer
    Thomas, Goehler
    Carla, Hannig
    Bert, Hildebrandt
    Joerg, Steighardt
    Franziska, Cygon
    Fabian, Meinert
    Alexander, Stein
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [4] FOLFOX / Bevacizumab (Beva) plus /- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
    Schmoll, H. J.
    Garlipp, B.
    Junghanss, C.
    Leithauser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
    Schmoll, Hans-Joachim
    Garlipp, Benjamin
    Junghanss, Christian
    Leithaeuser, Malte
    Vogel, Arndt
    Schaefers, Michael
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Florschuetz, Axel
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Steighardt, Joerg
    Meinert, Fabian Maximilian
    Cygon, Franziska
    Stein, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Efficacy and quality of life for FOLFOX/bevacizumab plus /- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
    Schmoll, Hans-Joachim
    Mann, Julia
    Meinert, Fabian
    Garlipp, Benjamin
    Borchert, Kersten
    Vogel, Arndt
    Goekkurt, Eray
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Roll, Carsten
    Bokemeyer, Carsten
    Steighardt, Joerg
    Cygon, Franziska
    Ibach, Stefan
    Stein, Alexander
    Tintelnot, Joseph
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (02) : 233 - 241
  • [7] Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
    Hans-Joachim Schmoll
    Julia Mann
    Fabian Meinert
    Benjamin Garlipp
    Kersten Borchert
    Arndt Vogel
    Eray Goekkurt
    Ulrich Kaiser
    Heinz-Gert Hoeffkes
    Jörn Rüssel
    Stephan Kanzler
    Thomas Edelmann
    Helmut Forstbauer
    Thomas Göhler
    Carla Hannig
    Bert Hildebrandt
    Carsten Roll
    Carsten Bokemeyer
    Jörg Steighardt
    Franziska Cygon
    Stefan Ibach
    Alexander Stein
    Joseph Tintelnot
    [J]. British Journal of Cancer, 2024, 130 : 233 - 241
  • [8] FOLFOX plus Bevacizumab (Bev) vs. FOLFOXIRI plus Bev in advanced Colorectal Cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
    Stein, A.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Roll, C.
    Steighardt, J.
    Meinert, F.
    Cygon, F.
    Schmoll, H-J
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 196 - 197
  • [9] FOLFOX-6 PLUS IMATINIB, BEVACIZUMAB AND CETUXIMAB IN ADVANCED UNTREATED COLORECTAL CANCER
    Andretta, V
    Bennicelli, E.
    Pessino, A.
    Caprioni, F.
    Decian, F.
    Di Benedetto, M.
    Sobrero, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 113 - 113
  • [10] Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer
    Oukkal, M.
    Kara, F.
    Difi, S.
    Bouzidi, D.
    Bentabak, K.
    Graba, A.
    Smail, N.
    Kaci, N. Ait
    Ahmed, R. Baba
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345